Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 1999, p. 1072-1076, Vol. 43, No. 5
Department of
Microbiology1 and First Department of
Internal Medicine,
Received 27 July 1998/Returned for modification 5 November
1998/Accepted 27 February 1999
The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated
for their in vitro antimicrobial activities against 44 strains of
Helicobacter pylori. Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of
isolates are inhibited for these drugs were lower (0.002 and 0.008 µg/ml, respectively) than those of amoxicillin and rifampin for
H. pylori. Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be
useful for the eradication of H. pylori infections.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vitro Anti-Helicobacter pylori
Activities of New Rifamycin Derivatives, KRM-1648 and
KRM-1657
*
Corresponding author. Mailing address: Department of
Microbiology, Yamaguchi University School of Medicine, 1144, kogushi, Ube, Yamaguchi 755-8505, Japan. Phone: 81-836-22-2226. Fax:
81-836-22-2227. E-mail:
nakazawa{at}po.cc.yamaguchi-u.ac.jp.
Antimicrobial Agents and Chemotherapy, May 1999, p. 1072-1076, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gisbert, J. P.
(2009). Review: Second-line rescue therapy of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology
2: 331-356
[Abstract] -
Rothstein, D. M., Farquhar, R. S., Sirokman, K., Sondergaard, K. L., Hazlett, C., Doye, A. A., Gwathmey, J. K., Mullin, S., van Duzer, J., Murphy, C. K.
(2006). Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection. Antimicrob. Agents Chemother.
50: 3658-3664
[Abstract] [Full Text] -
Anton, P. M., O'Brien, M., Kokkotou, E., Eisenstein, B., Michaelis, A., Rothstein, D., Paraschos, S., Kelly, C. P., Pothoulakis, C.
(2004). Rifalazil Treats and Prevents Relapse of Clostridium difficile-Associated Diarrhea in Hamsters. Antimicrob. Agents Chemother.
48: 3975-3979
[Abstract] [Full Text] -
Roblin, P. M., Reznik, T., Kutlin, A., Hammerschlag, M. R.
(2003). In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother.
47: 1135-1136
[Abstract] [Full Text] -
Okamoto, T., Yoshiyama, H., Nakazawa, T., Park, I.-D., Chang, M.-W., Yanai, H., Okita, K., Shirai, M.
(2002). A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother
50: 849-856
[Abstract] [Full Text] -
Heep, M., Odenbreit, S., Beck, D., Decker, J., Prohaska, E., Rieger, U., Lehn, N.
(2000). Mutations at Four Distinct Regions of the rpoB Gene Can Reduce the Susceptibility of Helicobacter pylori to Rifamycins. Antimicrob. Agents Chemother.
44: 1713-1715
[Abstract] [Full Text] -
Heep, M., Rieger, U., Beck, D., Lehn, N.
(2000). Mutations in the Beginning of the rpoB Gene Can Induce Resistance to Rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother.
44: 1075-1077
[Abstract] [Full Text]
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»